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Background:  Patients with type 2 diabetes have an increased risk of cardiovascular disease. Few studies have evaluated the car-
diovascular disease (CVD) risk simultaneously using the United Kingdom Prospective Diabetes Study (UKPDS) risk engine and 
non-invasive vascular tests in patients with newly diagnosed type 2 diabetes.
Methods:  Participants (n=380; aged 20 to 81 years) with newly diagnosed type 2 diabetes were free of clinical evidence of CVD. 
The 10-year coronary heart disease (CHD) and stroke risks were calculated for each patient using the UKPDS risk engine. Carotid 
intima media thickness (CIMT), flow mediated dilation (FMD), pulse wave velocity (PWV) and augmentation index (AI) were 
measured. The correlations between the UKPDS risk engine and the non-invasive vascular tests were assessed using partial cor-
relation analysis, after adjusting for age, and multiple regression analysis. 
Results:  The mean 10-year CHD and 10-year stroke risks were 14.92±11.53% and 4.03±3.95%, respectively. The 10-year CHD 
risk correlated with CIMT (P<0.001), FMD (P=0.017), and PWV (P=0.35) after adjusting for age. The 10-year stroke risk cor-
related only with the mean CIMT (P<0.001) after adjusting for age. FMD correlated with age (P<0.01) and systolic blood pres-
sure (P=0.09). CIMT correlated with age (P<0.01), HbA1c (P=0.05), and gender (P<0.01). 
Conclusion:  The CVD risk is increased at the onset of type 2 diabetes. CIMT, FMD, and PWV along with the UKPDS risk en-
gine should be considered to evaluate cardiovascular disease risk in patients with newly diagnosed type 2 diabetes. 
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INTRODUCTION
The prevalence of cardiovascular disease is 2 to 5 times higher 
in diabetics compared to non-diabetics [1-3]. Diabetes with 
no history of myocardial infarction are equally at risk for myo-
cardial infarction as are non-diabetic subjects with a history of 
myocardial infarction, and they are both classified in the same 
coronary artery disease risk group [4].
  Therefore, in order to prevent cardiovascular disease in type 
2 diabetes patients, identifying and correcting risk factors are 
considered important. In the past the studies have been main-
ly focused to find cardiovascular disease in type 2 diabetes. 
Currently, identifying patients who are at high risk for cardio-
vascular disease prior to development of apparent cardiovas-
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cular disease and preventing the disease have taken a higher 
priority. However, identifying patients who are at high risk for 
cardiovascular disease and require active prevention is not easy. 
A few cardiovascular risk models and vascular tests have been 
suggested to evaluate the risk of cardiovascular disease.
  Among cardiovascular disease risk models, through the 
United Kingdom Prospective Diabetes Study (UKPDS), the 
UKPDS risk engine was developed for estimating risk of coro-
nary heart disease and stroke for 10 years in type 2 diabetes 
[5,6]. UKPDS enrolled 5,100 patients who were newly diag-
nosed with type 2 diabetes and was originally aimed to know 
whether glycemic control could decrease morbidity and mor-
tality that were associated with diabetic complications [7]. 
Through the UKPDS, the relationships between cardiovascu-
lar diseases and identified general risk factors in type 2 diabe-
tes was investigated and the UKPDS risk engine was devel-
oped. 
  In vascular examinations to predict cardiovascular disease, 
flow-mediated dilation (FMD) assesses early endothelial cell 
dysfunction, and pulse wave velocity (PWV) and augmenta-
tion index (AI) assess arterial stiffness. Carotid intima-media 
thickness (CIMT) is used for early detection of atherosclerosis 
[8]. Vascular examinations evaluate the risk of cardiovascular 
disease because vascular dysfunction and changes in the vas-
cular structure occur before the onset of cardiovascular disease. 
These changes are not isolated but represent changes that oc-
cur in blood vessels throughout the entire body [9].
  There are no studies on the correlations between the UKP-
DS risk engine and blood vessel examinations in Korean type 
2 diabetes patients. In the present study, in order to assess the 
risk of cardiovascular disease in patients who were just diag-
nosed with type 2 diabetes, we used the UKPDS risk engine 
among cardiovascular disease risk models and easy and non-
invasive vascular examinations. The relationship between vas-
cular tests and the UKPDS risk engine as well as the relation-
ship between vascular tests and cardiovascular risk factors were 
investigated.
METHODS
Study subjects and anthropometric measurement
This study was performed between January 2003 and August 
2007 at the Eulji General Hospital Diabetes Center, and em-
ployed the use of 75 g oral glucose tolerance test to diagnose 
diabetes. The diagnostic criteria set by the American Diabetes 
Association were used to diagnose type 2 diabetes patients that 
participated in this study [10]. Individuals who had previously 
used oral hypoglycemic agents for over 1 month, had previous-
ly received insulin treatment, or had a history of cardiovascu-
lar disease were excluded from this study.
  Study participants answered a questionnaire regarding their 
disease history and were measured for height and weight. Par-
ticipants then had their blood pressures measured using a mer-
cury blood pressure monitor (Yamasu, Tokyo, Japan) after sit-
ting for 10 minutes to stabilize their blood pressure. Waist cir-
cumference measurements were performed by the same ex-
aminer at the middle point between the bottom of the ribcage 
and the iliac crest. Body mass index (BMI) was calculated by 
dividing body weight by height squared (kg/m
2).
Calculated risk of the UKPDS risk engine
Cardiovascular risk was scored for each participant using the 
UKPDS risk engine (version 2.0) by inputting risk factors such 
as age, gender, race, current smoking status, glycated hemoglo-
bin, systolic blood pressure, total cholesterol, high density lipo-
protein cholesterol (HDL-C), and presence or absence of atrial 
fibrillation, and the 10-year risk of coronary heart disease 
(CHD) and cerebrovascular disease were calculated [3,5,6].
Biochemical tests
Blood samples were taken after 8 hours of fasting, and blood 
glucose, cholesterol, triglycerides, and low density lipoprotein 
cholesterol (LDL-C) were measured on a Hitachi 7170 (Hita-
chi, Tokyo, Japan) using the enzymatic method. In addition, 
HDL-C and VLDL were measured after their precipitation.
Vascular examinations
Measuring CIMT 
CIMT was measured using a high resolution B-mode ultra-
sound (LOGIC 400 CL PRO; General Electric, Milwaukee, WI, 
USA) by the same well-trained examiner. Ultrasonography of 
the common carotid artery, carotid bifurcation, and internal 
carotid artery of the left and right carotid arteries was per-
formed. The distance between the leading edge of the first 
bright line of the far wall (lumen-intima interface) and the 
leading edge of the second bright line (media-adventitia inter-
face) indicates the intima-media thickness. The distance be-
tween the first and second bright lines was measured in the 
separations of the low bright regions of the CIMT ultrasound. 
The CIMT values used for this study were the means of 6 mea-621
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surements from different locations [11,12].
FMD 
In order to verify the functionality of vascular endothelial cells, 
using a high resolution B-mode 11 MHz ultrasound, the FMD 
in the brachial artery was measured using the method of Raita-
kari and Celermajer [13]. Patients fasted and abstained from 
drugs, alcohol, caffeine, and tobacco for over 8 hours prior to 
testing.
  Participants were stabilized in supine position, and the base-
line diameter of the brachial artery was measured using a high-
resolution B-mode ultrasonograph. A linear transducer was 
located 5 to 10 cm above the antecubital fossa, and the center 
of the brachial artery was set as a reference point. Under B-
mode, the diameter was defined from one side of the interface 
(m-line) of the intima and media of the blood vessel to the 
same part on the opposite side. In order to reduce variation 
during diameter measurements, it was measured at arterial 
branching points and at the end of the diastolic phase just be-
fore the origin of an R wave using electrocardiogram (ECG). 
After baseline diameter measurements were completed, the 
transducer was removed, and a blood pressure cuff was attached 
to the middle of the upper arm and set at 250 mm Hg. After 5 
minutes, we reduced the pressure on the cuff to 0 mm Hg and 
then removed the cuff. We then repositioned the transducer, 
and within the 50 seconds during which hyperemia sets in, we 
measured the maximum diameter of the brachial artery in-
creased due to hyperemia. For baseline diameter, the measure-
ments were calculated as percentages, and a flow mediated re-
sponse was observed.
Brachial-ankle pulse wave velocity (BaPWV)
The measurements were taken in the morning after 8 hours of 
fasting and 10 minutes of resting using a VP1000 waveform 
analyzer (Omron, Tokyo, Japan). This instrument measured a 
pulse wave from both upper extremities and ankles, and the 
time difference was measured using ECG signals. The distance 
was obtained using a formula based on height and was used to 
calculate pulse wave velocity [14]. The blood pressure in limbs 
was measured using the vibratory method, and the left, right, 
and mean BaPWV were measured simultaneously. The mean 
BaPWV was used for statistical analysis. 
AI
The peripheral arterial waveform was recorded from the radial 
artery using the Applanation tonometer aortic waveform anal-
ysis system (SphygmoCoR
®; AtCor Medical Pty Ltd., Sydney, 
Australia), and then, using a generalized transfer function, the 
AI was obtained by calculating aortic waveforms [15]. In order 
to eliminate the effects of patient medication, measurements 
were taken after 8 hours of fasting. In addition, in order to 
eliminate the effects of heart rate during measurements, AI75 
(augmentation index adjusted for 75 beats/min) was obtained 
and was used for statistical analysis. 
Statistical analysis 
Statistical analysis was performed on SPSS version 17.0 (SPSS 
Inc., Chicago, IL, USA) software. Data are expressed as the 
mean and standard deviation. The log values of variables that 
did not follow a normal distribution were calculated. In order 
to find a correlation between the vascular tests and the UKP-
DS risk engine which determined the 10-year CHD and 10-
year stroke risk , after adjusting for age, a partial correlation 
analysis and multiple regression were tested. An ANCOVA 
was tested for correlation between the categorical variables of 
risk factors and vascular examinations, and a multiple regres-
sion analysis was used for continuous variables. P values less 
than 0.05 were considered to be statistically significant.
RESULTS
Clinical characteristics of the subjects
Among the 380 participants, the mean age was 52 years (range, 
20 to 81 years). Three patients had atrial fibrillation and 114 
were smokers (Table 1). Fifty percent of the patients were obese 
(BMI ≥25 kg/m
2), 77% had high blood pressure (BP ≥130/80 
mm Hg), and 34% were taking antihypertensive medication. 
Ninety-four percent of patients had hypercholesterolemia, 
which was classified as total cholesterol ≥200 mg/dL, triglyc-
eride ≥150 mg/dL, LDL-C ≥100 mg/dL, or HDL-C (HDL-C; 
male, <40 mg/dL; female, <50 mg/dL).
The relevance of vascular tests and risk factors of 
cardiovascular disease
Among cardiovascular disease risk factors (age, gender, systol-
ic blood pressure, lipid abnormalities, glycated hemoglobin, 
smoking, and atrial fibrillation), CIMT increased with age 
(P<0.001) and glycated hemoglobin (P=0.048), decreased 
with HDL-C (P=0.450), and was significantly different based 
on gender (P<0.001). FMD decreased significantly with in-622
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creasing age (P<0.001) and systolic blood pressure (P=0.017). 
BaPWV increased with age (P<0.001) and total cholesterol 
(P<0.001). AI75 increased with HDL-C (P=0.034), and was 
different based on gender (P<0.001). No vascular tests were 
related to smoking or atrial fibrillation. The intraobserver co-
efficients of variation of FMD and AI were 47% and 51%, re-
spectively. Since there was only one examiner in this study, the 
interobserver coefficient of variation could not be calculated. 
Correlation between the UKPDS engine and vascular tests
In the entire participants in the study, the 10-year CHD risk 
and 10-year stroke risk calculated using the UKPDS risk en-
gine were 14.92% and 4.03%, respectively. The 10-year stroke 
risk was lower than 10-year CHD risk because there were only 
3 patients with atrial fibrillation in this study. The mean values 
of study population were 50 years old, smoker, a systolic blood 
pressure of 130 mm Hg, glycated hemoglobin of 8.64%, total 
cholesterol of 200 mg/dL, and HDL-C of 45 mg/dL. With 
these mean values, the 10-year stroke risk calculated using the 
UKPDS risk engine, in a male patient with and without a his-
tory of atrial fibrillation was 16.7% and 2.1%, respectively, 
which shows that atrial fibrillation has a large effect on the 10-
year stroke risk. Because of few atrial fibrillation patients, there 
was a difference between 10-year CHD risk and 10-year stroke 
risk in the present study. Prior to adjusting for age, the 10-year 
CHD risk and 10-year stroke risk were significantly correlated 
with FMD, BaPWV, and CIMT. However, there was no corre-
lation with AI75. The 10-year CHD and 10-year stroke risks 
both increased with age (Fig. 1). In addition, age was signifi-
cantly correlated with the all four vascular tests. After adjust-
ing for age, there was a significant correlation between the 10-
year CHD risk and CIMT (P<0.001), FMD (P<0.017), and 
BaPWV (P<0.035) and a significant correlation between the 
10-year stroke risk and CIMT (P<0.001) (Table 2). CIMT, 
FMD, BaPWV, age, and gender values were treated as inde-
pendent variables, and 10-year CHD risk was treated as a de-
pendent variable. Therefore, a multiple regression analysis 
confirmed age, gender, CIMT and BaPWV independently af-
fect 10-year CHD. The 10-year stroke risk was treated as a de-
pendent variable, age, gender, and CIMT were treated as inde-
pendent variables. Therefore, a multiple regression analysis 
confirmed age and gender affecting 10-year stroke risk (Table 
3).
DISCUSSION
Risk of cardiovascular disease calculated by the UKPDS 
risk engine
The Framingham risk score and SCORE [16] are risk models 
used to assess the risk of cardiovascular disease in the general 
population. The UKPDS risk engine is a risk model used only 
for diabetes patients. van der Heijden et al. [17] found that the 
UKPDS risk function was more accurate in predicting coro-
nary artery disease in a Hoorn study cohort of newly diag-
Table 1. Baseline characteristics of the study population
Characteristic Value
Age, yr 52.13±11.53
Sex, percentage males 58.95
SBP, mm Hg 126.95±13.82
DBP, mm Hg 80.01±9.20
Height, cm 163.72±8.55
BMI, kg/m
2 25.32±3.34
HbA1c, % 8.64±2.30
HOMA-IR 2.32±2.18
Total cholesterol, mg/dL 197.23±52.60
HDL-C, mg/dL 45.97±11.48
LDL-C, mg/dL 121.21±33.59
Lipid ratio, TG/HDL-C 4.50±1.71
Atrial fibrillation, % 0.79
Current smoker, % 30.16
 Ex-smoker, % 12.17
 Non-smoker, % 30.16
FMD, % increase in baseline diameter 5.92±3.04
BaPWV, m/sec 9.47±3.37
AI75, % 23.42±11.14
Mean IMT, mm 0.67±0.15
UKPDS 10-yr CHD risk, % 14.92±10.89
UKPDS 10-yr fatal CHD risk, % 8.16±8.02
UKPDS 10-yr stroke risk, % 4.03±3.95
UKPDS 10-yr fatal stroke risk, % 0.56±0.59
Values are presented as mean±standard deviation.
SBP, systolic blood pressure; DBP, diastolic blood pressure; BMI, 
body mass index; HOMA-IR, homeostasis model assessment of insu-
lin resistance; HDL-C, high density lipoprotein cholesterol; LDL-C, 
low density lipoprotein cholesterol; TG, triglyceride; FMD, flow-me-
diated dilation; PWV, pulse wave velocity; AI, augmentation index; 
IMT, intima-media thickness; UKPDS, United Kingdom Prospective 
Diabetes Study; CHD, coronary heart disease.623
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Table 2. Correlation of vascular function with the UKPDS risk engine and age in newly diagnosed type 2 diabetics
Unadjusted correlation  
(adjusted by height for AI) Age
Partial correlation, adjusted for age  
(and height for AI)
10-yr CHD risk
a 10-yr stroke risk
a 10-yr CHD risk
a 10-yr stroke risk
a
r P value r P value  r P value  r P value  r P value
CIMT
a 0.494 <0.001 0.565 <0.001 0.542 <0.001 0.282 <0.001 0.199 <0.001
FMD
a -0.326 <0.001 -0.368 <0.001 -0.346 <0.001 -0.164 0.017 -0.114 0.098
BaPWV
a 0.284 <0.001 0.317 <0.001 0.303 <0.001 0.121 0.035  0.001 0.988
AI75 0.058 0.553 0.141 0.146 0.169 0.075 -0.052 0.602 0.032 0.745
UKPDS, United Kingdom Prospective Diabetes Study; AI, augmentation index; CHD, coronary heart disease; CIMT, carotid intima-media thick-
ness; FMD, flow-mediated dilation; PWV, pulse wave velocity.
aUsing log transformed data.
nosed type 2 diabetes patients than were the Framingham and 
SCORE methods. The UKPDS studies only included newly 
diagnosed type 2 diabetes patients, and the UKPDS risk en-
gine used values of patients diagnosed within 1 to 2 years [17]. 
In the present study, performed on patients who were recently 
diagnosed with diabetes, the 10-year CHD risk and 10-year 
stroke risk were 14.92% and 4.03%, respectively, calculated us-
ing the UKPDS risk engine. The 10-year CHD risk was rela-
tively high, and the risk of coronary heart disease tended to 
increase after onset of type 2 diabetes. 
CIMT
CIMT increases from the onset of atherosclerosis. The Athero-
sclerosis Risk in Communities (ARIC) study examined CIMT 
in 5,552 males and 7,289 females, ages 45 to 64, followed for 
an average of 5.2 years between 1987 and 1993. Coronary heart 
disease was 1.85 times more prevalent in males and 5.07 times 
more prevalent in females who had a CIMT greater than 1 mm 
compared to those with a CIMT less than 1 mm [18]. In an-
other ARIC study that examined the relevance of CIMT and 
cerebrovascular disease over an average of 7.2 years, ischemic 
cerebrovascular disease was 1.78 times more prevalent in males 
and 2.02 times more prevalent in females with a CIMT greater 
than 1 mm compared to that of those with a CIMT less than 1 
mm [11]. One meta-analysis showed that type 2 diabetes pa-
tients had an average CIMT that was 0.13 mm greater than 
normal individuals, which was associated with a 40% greater 
probability of type 2 diabetics developing cardiovascular dis-
ease compared to healthy individuals [19]. 
  In a Korean study, Bae et al. [20] showed that the mean CIMT 
Fig. 1. Plot of 10-year coronary heart disease (CHD) and 10-year stroke risks according to age. (A) 10-year CHD risk. (B) 10-
year stroke risk.
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of healthy individuals with no risk factors for cardiovascular 
disease was 0.63±0.11 mm, and the mean CIMT of the dia-
betic study subjects was 0.75±0.17 mm. The mean CIMT of 
our patients (0.67±0.15 mm) was higher than that reported by 
Bae et al. Thus, even recently diagnosed type 2 diabetes pa-
tients have higher CIMT values than healthy individuals. 
  In this study, the 10-year CHD risk and the 10-year stroke 
risk calculated using the UKPDS risk engine and CIMT were 
positively correlated (P<0.001, respectively). Further, the CIMT 
and UKPDS risk engine were both effective methods to pre-
dict cardiovascular disease in recently diagnosed type 2 diabe-
tes patients. In multiple regression analyses, however, CIMT 
was not an independent influencing factor of 10-year stroke 
risk. 
  A study performed by Temelkova-Kurktschiev et al. [21] on 
newly diagnosed type 2 diabetes patients found no cardiovas-
cular risk factors that were associated with CIMT, despite few 
enrolled patients. Matsumoto et al. [22] showed that age, sys-
tolic blood pressure, glycated hemoglobin, and HDL-C were 
all associated with increases in CIMT in 438 type 2 diabetes 
patients. A study of Korean type 2 diabetes patients found that 
gender, smoking, systolic blood pressure, LDL, and glycated 
hemoglobin were significantly correlated with CIMT [12]. The 
differences in these results likely result from differences in the 
study populations. In our study, among the variables that com-
pose the risk score from the UKPDS risk engine, age (P<0.001), 
gender (P<0.001), and glycated hemoglobin (P=0.048) were 
all independent risk factors for CIMT, and a decrease in CIMT 
was associated with an increase in HDL-C (P=0.045). There-
fore, in recently diagnosed Korean type 2 diabetes patients, age, 
gender, glycated hemoglobin, and HDL-C are closely related. 
FMD
Endothelial cell dysfunction is associated with multiple car-
diovascular risk factors [23] and occurs early in atherosclero-
sis. Henry et al. [24] found a meaningful decrease in FMD in 
type 2 diabetes patients compared to healthy controls and an 
impaired glucose tolerance (IGT) group. Su et al. [25] assessed 
endothelial cell dysfunction in FMD in 46 control patients, 30 
impaired fasting glucose (IFG) patients, 38 IGT patients, and 
44 type 2 diabetes patients. The IGT group had a significantly 
lower FMD compared to the control group. Ravikumar et al. 
[26] reported an FMD of 6.64±4.38% in 50 control patients 
and 1.72±2.82% in 50 diabetic patients. A study of Korean pa-
tients by Shin et al. [27] showed that the FMD of type 2 diabe-
tes patients who had no history of cardiovascular complica-
tions was 7.6±0.2%, and the FMD of non-diabetics of similar 
age and gender was 8.9±0.4%. Our mean FMD was 
5.92±3.04%, which is lower than the mean FMD value from 
another Korean study of type 2 diabetes patients. Thus, the en-
dothelial cell function evaluated by FMD decreases in patients 
recently diagnosed with type 2 diabetes. 
  Until now, there have been very few studies on the relation-
ship between the calculated 10-year CHD risk using the UKP-
DS risk engine and FMD. In this study, only 10-year CHD risk 
was negative correlated with FMD (P=0.022). This is the first 
study that FMD and 10-year CHD risk has a significant corre-
lation in newly diagnosed Korean type 2 diabetes patients. This 
result suggests that FMD can predict coronary heart disease in 
newly diagnosed type 2 diabetes patients. 
  According to Celermajer et al. [28], endothelial cell func-
tion measured using FMD and cardiovascular risk factors 
such as smoking, hyperlipidemia, hypertension, gender, and 
age are all related. In a Korean study of 57 diabetes patients at 
an average of 10 years after diagnosis, there was no correlation 
between FMD and cardiovascular risk factors such as age, gly-
cated hemoglobin, or hyperlipidemia [27]. In our study, of 
cardiovascular risk factors included in the UKPDS risk engine, 
age (P<0.001) and systolic blood pressure (P=0.017) were sig-
nificantly correlated with FMD (Table 2). Smoking, hyperlip-
Table 3. Multiple regression analysis with 10-year CHD risk 
or 10-year stroke risk as the dependent variable
Variable
10-yr CHD risk
a 10-yr stroke risk
a
Coefficient  
(95% CI) P value
Coefficient  
(95% CI) P value
Age
0.015  
(0.013 to 0.017) <0.001
0.034  
(0.033 to 0.035) <0.001
Sex
-0.358  
(-0.385 to -0.331) <0.001
-0.224  
(-0.241 to -0.207) <0.001
CIMT
a 0.155  
(0.079 to 0.231) 0.042
0.064  
(0.018 to 0.110) 0.165
FMD
a -0.054  
(-0.083 to 0.025) 0.062
PWV
a 0.133  
(0.067 to 0.199) 0.046
Dependent variable: 10-year CHD risk, R
2=0.648, P<0.001 or 10-year 
stroke risk, R
2=0.878, P<0.001.
CHD, coronary heart disease; CI, confidence interval; CIMT, carotid 
intima-media thickness; FMD, flow-mediated dilation; PWV, pulse 
wave velocity.
aUsing log transformed data.625
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idemia, gender, and glycated hemoglobin had no association 
with FMD. These results confirmed that vascular function, as 
assessed by FMD, is closely related with age and systolic blood 
pressure in newly diagnosed type 2 diabetics.
PWV
Arterial stiffness measured by PWV increases as the risk of 
developing cardiovascular disease increases [29], and central 
arterial stiffness is more closely related to cardiovascular dis-
ease than is peripheral arterial stiffness [8]. Thus, carotid-fem-
oral PWV, which reflects central arterial stiffness, is frequently 
used in large-scale prospective studies. In Japan, the BaPWV, 
which is easy to measure and is far from the inguinal region, is 
commonly used [30]. However, BaPWV only reflects about 
60% of the central arterial stiffness and about 20% of the pe-
ripheral arteries [31].
  Although Blacher et al. [32] used a different PWV method, 
they reported a close association between cardiovascular dis-
ease and a carotid-femoral PWV greater than 13 m/sec. Our 
study reported a lower mean BaPWV of 9.47±3.37 m/sec in 
patients with a mean age of 52 years. However, in a study of 
healthy Koreans with an age of 50 to 60 years, the mean BaP-
WV was 7.84±2.37 m/sec and it was lower than our result, 
supporting that arterial stiffness increases in the initial stages 
of type 2 diabetes [33]. Additionally, our PWV results are con-
sistent with results reported by Cruickshank et al. [34] that 
PWV tends to increase more in type 2 diabetics than in a nor-
mal control group. Additionally, BaPWV correlated with the 
10-year CHD risk (P=0.035) calculated by the UKPDS risk 
engine. A correlation between only 10 year risk calculated by 
the UKPDS risk engine and BaPWV are likely because BaP-
WV does not reflect the stiffness of the central artery as well as 
carotid-femoral PWV. Therefore, further prospective studies 
are required to correlate cardiovascular disease and arterial 
stiffness. 
AI
The interaction between the incident pulse wave (from the 
heart to the periphery) and the reflected pulse wave (from the 
periphery to the central region) is assessed by pulse wave anal-
ysis and expressed as the AI. Systemic arterial stiffness and 
changes in central arterial pressure are included as well, thus 
AI reflects both micro- and macrovascular function [8]. 
  In a study of 2,232 individuals from the Framingham heart 
study cohort who participated in the study for an average of 
7.8 years, Mitchell et al. [29] reported that there was no associ-
ation between AI and cardiovascular disease. This was consis-
tent with a study of hypertensive elderly women that was un-
able to predict cardiovascular disease using AI [35]. In a pa-
tient group that included 20% diabetics, however, an increase 
in AI reflected an increase in the prevalence of cardiovascular 
disease [15]. In a Hoorn study, AI increased in type 2 diabet-
ics, but there was no difference between the IGT and normal 
control groups [36]. We observed no correlation between the 
UKPDS risk engine and AI. Since there are conflicting results 
on the association between AI and cardiovascular disease, ad-
ditional research is required on Korean type 2 diabetics before 
using AI clinically in these patients. 
  This study has several limitations. First, it was a cross-sec-
tional study so there was no way to confirm causal relation-
ships. Second, there was no control group for comparing vas-
cular tests. Although we cannot confirm the extent of vascular 
dysfunction or atherosclerosis by comparing to other studies, 
to evaluate our results, we compared our results to those of a 
domestic study that used the same examination methods on 
patients from the same age group. Third, the intraobserver co-
efficient of variation for AI and PVW were high, and the reli-
ability of these tests was low. 
  In conclusion, the increased risk of cardiovascular disease 
at the onset of type 2 diabetes observed in this study is consis-
tent with previous studies. In our study of the relationships 
between the UKPDS risk engine and vascular tests, the 10-year 
CHD risk was correlated with CIMT, FMD, and PWV, and the 
10-year stroke risk was correlated with CIMT. Therefore, in 
order to accurately predict the risk of cardiovascular disease in 
Korean type 2 diabetics, future studies should focus on an ad-
ditional prospective studies using the UKPDS risk engine with 
CIMT, FMD, and PWV.
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